Corcept says ROSELLA trial hit key endpoint for relacorilant combo

US biopharma Corcept Therapeutics (Nasdaq: CORT) says its Phase III ROSELLA trial met its overall survival primary endpoint for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, adding fresh momentum to the company’s regulatory push.

In the 381-patient study, Corcept said the combination reduced the risk of death by 35% versus nab-paclitaxel alone. Median overall survival was 16.0 months with relacorilant versus 11.9 months with chemotherapy alone, a 4.1-month difference.

Corcept said the regimen was well tolerated and the type, frequency, and severity of adverse events were comparable between the combination arm and nab-paclitaxel monotherapy, arguing the drug delivered benefit without adding to treatment burden.